These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates. Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884 [TBL] [Abstract][Full Text] [Related]
7. Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. Roth JD; Coffey T; Jodka CM; Maier H; Athanacio JR; Mack CM; Weyer C; Parkes DG Endocrinology; 2007 Dec; 148(12):6054-61. PubMed ID: 17761760 [TBL] [Abstract][Full Text] [Related]
8. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845 [TBL] [Abstract][Full Text] [Related]
9. Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids. Trevaskis JL; Mack CM; Sun C; Soares CJ; D'Souza LJ; Levy OE; Lewis DY; Jodka CM; Tatarkiewicz K; Gedulin B; Gupta S; Wittmer C; Hanley M; Forood B; Parkes DG; Ghosh SS PLoS One; 2013; 8(10):e78154. PubMed ID: 24167604 [TBL] [Abstract][Full Text] [Related]
10. Simultaneous quantification of the glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK) receptor agonists in rodent plasma by on-line solid phase extraction and LC-MS/MS. Wang Y; Roth JD; Taylor SW J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Apr; 957():24-9. PubMed ID: 24657407 [TBL] [Abstract][Full Text] [Related]
11. Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents. Roth JD; D'Souza L; Griffin PS; Athanacio J; Trevaskis JL; Nazarbaghi R; Jodka C; Athanacio J; Hoyt J; Forood B; Parkes DG Diabetes Obes Metab; 2012 Jul; 14(7):608-15. PubMed ID: 22276636 [TBL] [Abstract][Full Text] [Related]
12. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents. Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027 [TBL] [Abstract][Full Text] [Related]
13. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice. Irwin N; Hunter K; Montgomery IA; Flatt PR Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064 [TBL] [Abstract][Full Text] [Related]
14. A GLP-1/glucagon (GCG)/CCK Zhao S; Yan Z; Du Y; Li Z; Tang C; Jing L; Sun L; Yang Q; Tang X; Yuan Y; Han J; Jiang N Br J Pharmacol; 2022 Sep; 179(17):4360-4377. PubMed ID: 35484823 [TBL] [Abstract][Full Text] [Related]
16. Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents. Yang Q; Zhou F; Tang X; Wang J; Feng H; Jiang W; Jin L; Jiang N; Yuan Y; Han J; Yan Z Eur J Med Chem; 2022 Apr; 233():114214. PubMed ID: 35231829 [TBL] [Abstract][Full Text] [Related]
17. Exogenous glucagon-like peptide-1 reduces body weight and cholecystokinin-8 enhances this reduction in diet-induced obese male rats. Mhalhal TR; Washington MC; Newman K; Heath JC; Sayegh AI Physiol Behav; 2017 Oct; 179():191-199. PubMed ID: 28647503 [TBL] [Abstract][Full Text] [Related]
18. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168 [TBL] [Abstract][Full Text] [Related]
19. Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet. Sakai T; Kusakabe T; Ebihara K; Aotani D; Yamamoto-Kataoka S; Zhao M; Gumbilai VM; Ebihara C; Aizawa-Abe M; Yamamoto Y; Noguchi M; Fujikura J; Hosoda K; Inagaki N; Nakao K Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E712-9. PubMed ID: 25159327 [TBL] [Abstract][Full Text] [Related]
20. Discovery of once-weekly, peptide-based selective GLP-1 and cholecystokinin 2 receptors co-agonizts. Zhou F; Song P; Tang X; Yang Q; Zhou S; Xu R; Fang T; Jia Z; Han J Peptides; 2022 Jul; 153():170811. PubMed ID: 35594964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]